Truist analyst Jailendra Singh upgraded Doximity (DOCS) to Buy from Hold with a $62 price target Doximity continues to gain market share and outperform the HCP pharma digital marketing industry, with its OpenEvidence tools showing promise despite adoption still developing, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity upgraded to Buy from Hold at Truist
- Doximity price target lowered to $60 from $75 at KeyBanc
- Doximity price target lowered to $48 from $58 at Canaccord
- Doximity price target raised to $50 from $48 at Canaccord
- Doximity: Compelling Long Opportunity Amid Overdone Competitive Fears and Undervalued AI-Driven Growth